The Daily Toke

March 25, 2026

Hawaii's legislature is moving quickly on psychedelics policy while other states grapple with basic cannabis regulation, revealing a striking split in how American lawmakers approach drug normalization. The Hawaii House Health Committee advanced a bipartisan bill on Friday that would create a Mental Health Emerging Therapies Task Force to study and recommend implementation pathways for psilocybin and MDMA—substances the FDA has already designated as breakthrough therapies. The measure passed unanimously in the Senate (24-0) and advanced in the House committee (9-0) despite dealing with substances still classified as Schedule I at the federal level. Hawaii's Department of Health and the Governor's Office of Wellness and Resilience both testified in support, framing the two-year research initiative as essential preparation for what could be federal rescheduling. 🚀 THIS IS COOL The bill explicitly acknowledges the growing clinical evidence: psilocybin and MDMA show significant efficacy in treating PTSD, treatment-resistant depression, substance use disorders, and end-of-life anxiety—conditions that affect veterans, first responders, and trauma survivors in measurable, documented ways.

Meanwhile, Pennsylvania remains deadlocked on something far simpler: basic marijuana legalization and which government agency should oversee it. Governor Josh Shapiro's 2026-27 budget assumes lawmakers will legalize recreational cannabis and generate $729 million in new revenue to help close a $5 billion budget gap—yet his identical proposal failed last year over a single jurisdictional dispute. 💰 MONEY MOVES The dispute centers on whether a new Cannabis Control Board or the existing Liquor Control Board (LCB) should regulate the market. Republican Sen. Dan Laughlin chairs the key Senate committee and insists on creating the Cannabis Control Board; Democratic Rep. Dan Frankel, who leads the House Health Committee, prefers the LCB model because it has proven expertise in managing youth access and public health for alcohol. Frankel is "open to discussion," but the impasse has persisted for at least two legislative cycles. Pennsylvania's divided government means neither chamber will move forward without alignment on this foundational question.

Texas moved in a different direction entirely: on March 31, state health officials will ban smokeable intoxicating hemp products, including pre-rolled joints and hemp flower. 🤔 THINK ABOUT IT The timing is striking—Texas moves to eliminate legal hemp-derived intoxicating products just as Hawaii advances psychedelics research and Pennsylvania debates whether to legalize cannabis. Each state is making a distinct policy choice about which chemical compounds deserve access and which deserve restriction. Texas's ban targets the one cannabis product that has achieved legal status in prohibition states: federally compliant hemp with less than 0.3% Delta-9 THC. For veterans and chronic pain patients in Texas who were using hemp-derived products as a workaround while cannabis remained illegal, this eliminates a legal option and potentially pushes users toward unregulated or illicit markets.

Mississippi's medical marijuana ambitions largely stalled. Two bills survived the Senate committee and await the governor's signature, marking a notable retreat from larger reform hopes earlier in the session. The state now joins the patchwork: Hawaii researching psychedelics with federal-level support, Pennsylvania debating legalization logistics, Texas banning legal hemp, and Mississippi maintaining restrictive medical access. None of these outcomes are coordinated. None reflect a national strategy. What emerges instead is a picture of state-level experimentation driven by local politics, budget pressures, and jurisdictional disputes rather than consistent public health evidence. Hawaii's unanimous votes on psychedelics research suggest that when the science is unambiguous—when the FDA has already acted—bipartisan agreement is possible. The Pennsylvania deadlock suggests that agreement breaks down quickly when commerce and regulatory turf battles enter the equation. The Texas ban and Mississippi's modest progress suggest that in restrictive states, momentum still runs toward limitation rather than access, despite mounting evidence that cannabis and psychedelics warrant serious therapeutic consideration.

March 25, 2026

Smokeable hemp products are disappearing from American shelves in a coordinated wave of state-level bans that's reshaping one of the fastest-growing cannabis markets in the country. Texas will prohibit smokeable intoxicating hemp—including pre-rolled joints and hemp flower—effective March 31, following Ohio's ban that took effect this week. A Franklin County judge rejected a last-minute legal challenge to Ohio's restrictions, which also targeted THC and CBD beverages under Senate Bill 56, clearing gas stations and convenience stores across Central Ohio as regulators enforced the new rules. 💰 MONEY MOVES The timing matters: these aren't isolated actions but part of a national pattern as states from South Carolina to Pennsylvania grapple with what lawmakers are calling the "Wild West" of hemp products—a legal gray area that emerged directly from the 2018 federal Farm Bill, which legalized hemp containing 0.3 percent or less delta-9 THC by dry weight, but created a loophole when that same hemp is processed into edibles, drinks, and smokables where individual servings can contain significantly higher THC concentrations.

The regulatory momentum is accelerating despite industry pushback. South Carolina's Senate just advanced sweeping hemp regulations that would restrict purchases to adults 21 and over, ban on-premise consumption at bars and restaurants, limit gummy potency to 10 milligrams per piece with four pieces per pack, and move higher-potency drinks into liquor stores only. Some senators wanted an outright ban—a position echoed by the South Carolina Republican Party in an official resolution—while others argued for regulation rather than prohibition. Meanwhile, Pennsylvania lawmakers in Berks County are calling for state action on THC product concentration and sales restrictions. State Senator Judy Schwank drafted a bill to ban Delta-8 THC back in 2022 that stalled, but she's now looking at new legislation requiring legitimate testing, labeling, age restrictions, and stricter penalties. State Representative Manny Guzman framed the problem plainly: "It's like the wild west. We really need to find where we can actually regulate these products."

The regulatory fracture creates real questions about federal-state coordination and market viability. 🤔 THINK ABOUT IT These bans target products derived from federally legal hemp—the same plant that's explicitly protected under the Farm Bill—yet states are moving to restrict them anyway, leaving retailers and small businesses caught between conflicting legal frameworks. Texas's March 31 deadline will force retailers across the state to pull popular products and adjust business models on short notice. The bans target smokeable and ingestible forms while the regulatory debate rages over whether the products pose genuine public health risks or whether the concern is more about perception, potency comparisons to alcohol, and what some describe as fearmongering. Democrats in South Carolina pushed back against an outright ban, pointing to medicinal use and the small businesses that could be harmed. What's not in serious dispute: the products exist in a legal gray area, there's minimal federal oversight, and state-level regulation remains inconsistent at best. The question now is whether states will settle on uniform regulations that allow legal sales with safeguards, or whether bans will become the default, pushing the market underground or toward neighboring states where products remain legal.

March 25, 2026

# THC in Science: Major Study Contradicts Millions Using Cannabis for Mental Health

A landmark review published in The Lancet has upended assumptions held by roughly half of America's medical cannabis users. Researchers from the University of Sydney analyzed the largest body of evidence to date on medicinal cannabis and mental health, concluding that cannabinoids show little to no effectiveness for anxiety, depression, and PTSD—despite millions relying on the plant for exactly those conditions. The finding arrives at a critical moment: approximately 27 percent of people aged 16-65 in the United States and Canada report using cannabis medically, and about half cite mental health management as their primary reason.

Dr. Jack Wilson, lead author at the University of Sydney's Matilda Centre, delivered a sobering assessment: routine use of medicinal cannabis could actually be causing harm. The research identified real risks—increased psychotic symptoms, cannabis use disorder, and delayed access to proven treatments—suggesting that for anxiety, depression, and PTSD, "the use of medicinal cannabis in these cases are rarely justified." The study did identify limited evidence for other conditions including autism, insomnia, and cannabis dependency itself, though Wilson emphasized the supporting data remains weak. 🚀 THIS IS COOL On the positive side, the review confirmed stronger evidence for cannabis treating certain forms of epilepsy, reducing spasticity in multiple sclerosis patients, and managing chronic pain—areas where the science stands on firmer ground. Separately, a Hebrew University team found that cannabis compounds CBD and CBG showed promise in mouse models of non-alcoholic fatty liver disease, which affects about 24 percent of American adults, though human trials remain pending. Another breakthrough: researchers identified a cannabis compound showing potential in fighting Alzheimer's by calming brain inflammation, suggesting new mechanisms for neurological benefit beyond traditional pain and seizure management.

The mental health findings come as the federal government moves in the opposite direction. 💰 MONEY MOVES The Centers for Medicare & Medicaid Services announced a pilot program launching April 1 allowing up to $500 annually in hemp-derived CBD products for Medicare beneficiaries—and the products can contain up to 3 milligrams of THC. However, the announcement has triggered pushback from pharmaceutical and regulatory circles questioning whether CMS is circumventing FDA drug approval standards. Critics argue that allowing cannabinoid products as medical treatments without formal FDA review sets a dangerous precedent, blurring lines between supplements and medicines. Meanwhile, Congress remains fractured on cannabis policy: 16 bills have been filed in the current 2025-2026 session, with the MORE Act (seeking full federal legalization and automatic expungement) leading with 62 sponsors, while the Hemp Planting Predictability Act—a bipartisan effort to delay new federal hemp restrictions—has gathered 36 sponsors across both chambers.

On the product science side, 🚀 THIS IS COOL a new study in the Journal of Pharmaceutical and Biomedical Analysis found that powder-based CBD formulations dramatically outperform oil-based systems in stability. A cyclodextrin-based powder retained over 90 percent of CBD under standard conditions compared to roughly 20 percent retention in oil when exposed to light. Even at elevated temperatures, the powder maintained 86-87 percent potency while oil formulations degraded significantly and produced six times more unwanted byproducts. This matters: CBD is notoriously vulnerable to heat, light, and oxygen, and better formulation could extend shelf life and improve consistency across medical and consumer products.

Several states are charting independent paths. Utah Governor Spencer Cox signed legislation supporting clinical trials into psychedelic-assisted therapy for military veterans with serious mental health conditions, acknowledging that conventional treatments sometimes fail populations like combat veterans. Georgia lawmakers passed a medical cannabis expansion allowing vaping, adding new qualifying conditions, and increasing THC potency limits—sending it to the governor's desk. Colorado's cannabis compliance picture remains strong: a state report showed a 99 percent success rate in underage sales checks among retailers, suggesting that regulated markets can enforce age restrictions effectively.

🤔 THINK ABOUT IT The Sydney study suggests millions of cannabis users are self-medicating for mental health conditions where the evidence shows the plant doesn't help—and may hurt. Yet the federal government is simultaneously expanding insurance coverage for cannabinoid products while the FDA has approved only a handful of cannabinoid-based drugs through its rigorous process. The contradiction raises a real question: if cannabis lacks strong evidence for anxiety and depression, why expand Medicare coverage? And if it's genuinely therapeutic for specific conditions, why not pursue FDA approval pathways that would clarify which uses are supported by science? The answer likely involves politics, money, and the messy reality that cannabis policy remains driven more by campaign finance and state economics than by clinical outcomes.

March 25, 2026

Texas will ban smokeable hemp cannabis products effective March 31, 2026, eliminating one of the state's fastest-growing market segments in a regulatory shift that industry leaders say will force closures and drive consumers toward unregulated alternatives. The Texas Department of State Health Services adopted new rules in early March that redefine how the state measures total THC content—now counting THCA (tetrahydrocannabinolic acid) alongside delta-9 THC in the calculation. THCA is naturally present in hemp flower and concentrates, and when heated or smoked, converts into delta-9 THC. The change effectively bans smokeable products while leaving edibles, beverages, topicals, and other non-inhalable consumables untouched, provided they meet the new 0.3% total THC threshold per product.

💰 MONEY MOVES The regulatory overhaul includes a staggering jump in licensing fees: retail registrations will climb from $155 to $5,000 annually per location, while manufacturer fees jump from $258 to $10,000—increases of roughly 3,100% and 3,900% respectively. Industry operators say these dual pressures—losing 50% to 70% of inventory while tripling operational costs—will force small businesses to close. Jacob Warner, co-owner of Alamo Bud Co. in San Antonio, told reporters that smokeable products account for 70% of his sales. Allen Kirk, managing partner at Full Spectrum in San Angelo, estimated THCA products represent 35% to 50% of his store's revenue. Kirk expressed particular concern about veterans who rely on smokeable products for faster symptom relief—a joint or flower hits in minutes, while gummies and oils take 45 minutes to 90 minutes to activate. "Customers are going to go back to the street," Kirk warned. "They're going to buy sketchy products from sketchy individuals."

The ban arrives after Texas lawmakers spent months last year debating whether to impose comprehensive regulations or an outright prohibition on intoxicating hemp products. Governor Greg Abbott vetoed a total ban in summer 2025, then issued Executive Order GA-56 in September directing state health officials to tighten hemp regulations instead. Industry observers note the regulatory pathway was designed to avoid a legislative ban, but the outcome—eliminating the state's most popular smokeable products—mirrors a prohibition in effect. Heather Fazio, director of the Texas Cannabis Policy Center, criticized the four-week implementation window as unrealistic for businesses to pivot inventory and operations. "Imagine being a business and finding out that not only are your registration fees going up significantly, but also 50%—maybe even 70%—of the products that you sell now have to be taken off the shelves in a matter of weeks," she said. At least one East Texas vape shop has already filed suit to block the rules.

🤔 THINK ABOUT IT Texas banned marijuana entirely in 1937, then inadvertently legalized a multibillion-dollar hemp industry through the 2018 federal Farm Bill and a 2019 state law. That legal loophole allowed manufacturers to grow high-THCA hemp, which consumers smoke to get high without technically violating Texas marijuana prohibition. Now the state is closing that loophole through regulatory redefinition rather than legislation—a technical move that achieves prohibition's practical effect. Meanwhile, alcohol remains fully legal, kills approximately 95,000 Americans annually, and generates substantial tax revenue for Texas. Cannabis has never caused an overdose death in recorded history. The regulatory message appears to be: we'll tolerate intoxication from a substance that kills tens of thousands yearly, but not from a plant with zero overdose deaths—as long as the legal framework stays technically consistent.

The new rules also mandate stricter age verification (customers must be 21), enhanced product testing, child-resistant packaging, and more detailed recordkeeping by retailers and manufacturers. Supporters including Governor Abbott argue these measures improve consumer safety and create comprehensive oversight of an industry that exploded largely unregulated. The Texas Hemp Business Council and other industry groups acknowledge some regulations were needed, but contend the THCA reclassification and fee structure crossed into de facto prohibition without legislative debate or a grace period for compliance. Products already on shelves must be removed by March 31 or remain subject to enforcement action. Retailers report some competitors have already begun shutting down locations in anticipation of the deadline.